News Releases
View printer-friendly version < < backNEW BRUNSWICK, N.J., July 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.2 billion for the second quarter of 2009, a decrease of 7.4% as compared to the second quarter of 2008. Operational results declined 1.4% and the negative impact of currency was 6.0%. Domestic sales declined 6.7%, while international sales declined 8.0%, reflecting operational growth of 3.9% and a negative currency impact of 11.9%.
Net earnings and diluted earnings per share for the second quarter of 2009 were $3.2 billion and $1.15, respectively. The second quarter of 2008 included an after-tax in-process research and development charge of $40 million. Excluding this charge, net earnings for the quarter and diluted earnings per share represent decreases of 4.7% and 2.5%, respectively, as compared to the same period in 2008.* The Company confirmed its earnings guidance for full-year 2009 of $4.45 - $4.55 per share, which excludes the impact of special items.
"I am proud of the accomplishments of our people in continuing to deliver very solid operational results in light of the significant impacts of patent expirations and the economic environment," said William C. Weldon, Chairman and Chief Executive Officer. "Our investments through internal research and development, strategic partnerships and acquisitions have allowed us to build what is considered by many to be one of the best pipelines in our industry. We will continue to invest in our portfolio of innovative products to meet the needs of patients and consumers around the world."
Worldwide Consumer sales of $3.9 billion for the second quarter represented a decrease of 4.5% versus the prior year with an increase of 3.1% operationally and a negative impact from currency of 7.6%. Domestic sales increased 0.8%; while international sales decreased 8.4%, which reflected an operational increase of 4.7% and a negative currency impact of 13.1%.
LISTERINE® antiseptic mouthrinse and the skin care lines of NEUTROGENA® and AVEENO® contributed to operational sales growth during the quarter. Other growth drivers were sales from the recently completed acquisition of the French company Vania Expansion SNC.
Worldwide Pharmaceutical sales of $5.5 billion for the second quarter represented a decrease versus the prior year of 13.3% with an operational decline of 8.5% and a negative impact from currency of 4.8%. Domestic sales decreased 16.4%; while international sales decreased 8.7%, which reflected an operational increase of 3.3% and a negative currency impact of 12.0%.
REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; and CONCERTA® (methylphenidate HCI), a treatment for attention deficit hyperactivity disorder, had strong operational sales performance during the quarter. Sales results of TOPAMAX® (topiramate), an anti-epileptic, and RISPERDAL® (risperidone), an antipsychotic medication, were negatively impacted by generic competition.
During the quarter, the U.S. Food and Drug Administration (FDA) approved SIMPONI™ (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate, active psoriatic arthritis with or without methotrexate, and active ankylosing spondylitis. The FDA also approved the Supplemental New Drug Applications (sNDAs) for the use of RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of Bipolar I Disorder. The Drug Enforcement Administration (DEA) issued their final ruling and placed NUCYNTA™ (tapentadol) CII immediate release tablets for the relief of moderate to severe acute pain in patients 18 years of age or older into Schedule II of the Controlled Substances Act. The product is now available to patients.
The Company also announced a definitive agreement to acquire Cougar Biotechnology, a development stage biopharmaceutical company with a specific focus on oncology, for approximately $1.0 billion in a cash tender offer. On July 9, 2009, the acquisition of Cougar Biotechnology was completed. On July 2, 2009, the Company announced a definitive agreement with Elan Corporation, plc. whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program and will invest $1 billion in Elan newly issued American Depositary Receipts (ADRs).
Worldwide Medical Devices and Diagnostics sales of $5.9 billion for the second quarter represented a decrease of 3.1% versus the prior year with an operational increase of 2.9% and a negative currency impact of 6.0%. Domestic sales increased 1.9%; while international sales decreased 7.2%, which reflected an operational increase of 3.7% and a negative currency impact of 10.9%.
Primary contributors to the operational growth included Ethicon's surgical care products; Ortho-Clinical Diagnostics' professional products; Ethicon Endo-Surgery's minimally invasive products; and DePuy's orthopaedic joint reconstruction, spine, and sports medicine businesses. Also contributing to growth were sales of products acquired as part of the completed acquisition of Mentor Corporation, a leading supplier of medical products for the global aesthetic market. This growth was partially offset by lower sales in the Cordis franchise, reflecting new competitive entries in the drug-eluting stent market as well as the 2008 divestiture of the Professional Wound Care products in our Ethicon business.
About Johnson & Johnson
Caring for the world, one person at a time. . .inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 117,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
* Net earnings and diluted earnings per share excluding special items, such as after-tax in-process research and development charges, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the Investor Relations section of the Company's website at www.jnj.com.
NOTE TO INVESTORS
Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson can be found on the Company's website at www.jnj.com.
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited; Dollars in Millions) SECOND QUARTER
------------------------------- --------------
Percent Change
--------------
2009 2008 Total Operations Currency
--------------------- ---- ---- ----- ---------- --------
Sales to customers by
segment of business
Consumer
U.S. $1,708 1,694 0.8% 0.8 -
International 2,146 2,342 (8.4) 4.7 (13.1)
----------------- ----- ----- ---- --- -----
3,854 4,036 (4.5) 3.1 (7.6)
----- ----- ---- --- ----
Pharmaceutical
U.S. 3,172 3,793 (16.4) (16.4) -
International 2,326 2,547 (8.7) 3.3 (12.0)
----------------- ----- ----- ---- --- -----
5,498 6,340 (13.3) (8.5) (4.8)
----- ----- ----- ---- ----
Med Devices & Diagnostics
U.S. 2,776 2,723 1.9 1.9 -
International 3,111 3,351 (7.2) 3.7 (10.9)
----------------- ----- ----- ---- --- -----
5,887 6,074 (3.1) 2.9 (6.0)
----- ----- ---- --- ----
U.S. 7,656 8,210 (6.7) (6.7) -
International 7,583 8,240 (8.0) 3.9 (11.9)
------------- ----- ----- ---- --- -----
Worldwide $15,239 16,450 (7.4)% (1.4) (6.0)
--------- ------- ------ ---- ---- ----
(Unaudited; Dollars in Millions) SIX MONTHS
------------------------------- ----------
Percent Change
--------------
2009 2008 Total Operations Currency
--------------------- ---- ---- ----- ---------- --------
Sales to customers by
segment of business
Consumer
U.S. $3,434 3,513 (2.2)% (2.2) -
International 4,131 4,587 (9.9) 3.6 (13.5)
----------------- ----- ----- ---- --- -----
7,565 8,100 (6.6) 1.0 (7.6)
----- ----- ---- --- ----
Pharmaceutical
U.S. 6,846 7,863 (12.9) (12.9) -
International 4,432 4,906 (9.7) 3.1 (12.8)
----------------- ----- ----- ---- --- -----
11,278 12,769 (11.7) (6.8) (4.9)
------ ------ ----- ---- ----
Med Devices & Diagnostics
U.S. 5,428 5,311 2.2 2.2 -
International 5,994 6,464 (7.3) 3.6 (10.9)
----------------- ----- ----- ---- --- -----
11,422 11,775 (3.0) 3.0 (6.0)
------ ------ ---- --- ----
U.S. 15,708 16,687 (5.9) (5.9) -
International 14,557 15,957 (8.8) 3.5 (12.3)
------------- ------ ------ ---- --- -----
Worldwide $30,265 32,644 (7.3)% (1.3) (6.0)
--------- ------- ------ ---- ---- ----
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited; Dollars in Millions) SECOND QUARTER
-------------------------------- --------------
Percent Change
--------------
2009 2008 Total Operations Currency
---- ---- ----- ---------- --------
Sales to customers by
geographic area
U.S. $7,656 8,210 (6.7)% (6.7) -
---- ------ ----- ---- ---- ---
Europe 3,972 4,547 (12.6) 1.8 (14.4)
Western Hemisphere
excluding U.S. 1,215 1,280 (5.1) 11.7 (16.8)
Asia-Pacific, Africa 2,396 2,413 (0.7) 3.7 (4.4)
-------------------- ----- ----- ---- --- ----
International 7,583 8,240 (8.0) 3.9 (11.9)
------------- ----- ----- ---- --- -----
Worldwide $15,239 16,450 (7.4)% (1.4) (6.0)
--------- ------- ------ ---- ---- ----
(Unaudited; Dollars in Millions) SIX MONTHS
------------------------------- ----------
Percent Change
--------------
2009 2008 Total Operations Currency
---- ---- ----- ---------- --------
Sales to customers by
geographic area
U.S. $15,708 16,687 (5.9)% (5.9) -
--------------------- ------- ------ ---- ---- ---
Europe 7,643 8,855 (13.7) 0.8 (14.5)
Western Hemisphere
excluding U.S. 2,277 2,525 (9.8) 8.2 (18.0)
Asia-Pacific, Africa 4,637 4,577 1.3 5.9 (4.6)
-------------------- ----- ----- --- --- ----
International 14,557 15,957 (8.8) 3.5 (12.3)
------------- ------ ------ ---- --- -----
Worldwide $30,265 32,644 (7.3)% (1.3) (6.0)
--------- ------- ------ ---- ---- ----
Johnson & Johnson and Subsidiaries
-----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except
Per Share Figures) SECOND QUARTER
------------------------------ --------------
2009 2008 Percent
---------------- ------------------
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
------------------ ------ -------- ------ -------- ---------
Sales to customers $15,239 100.0 $16,450 100.0 (7.4)
------------------ ------- ----- ------- ----- ----
Cost of products
sold 4,450 29.2 4,751 28.9 (6.3)
Selling, marketing
and administrative
expenses 4,797 31.5 5,507 33.5 (12.9)
Research &
development expense 1,638 10.7 1,896 11.5 (13.6)
In-process research
& development - - 40 0.2
Interest (income)
expense, net 85 0.6 16 0.1
Other (income)
expense, net 6 - (135) (0.8)
-------------- --- --- ---- ---- ----
Earnings before
provision for taxes
on income 4,263 28.0 4,375 26.6 (2.6)
Provision for taxes
on income 1,055 6.9 1,048 6.4 0.7
------------------- ----- --- ----- --- ---
Net earnings $3,208 21.1 $3,327 20.2 (3.6)
------------ ------ ---- ------ ---- ----
Net earnings per
share (Diluted) $1.15 $1.17 (1.7)
Average shares
outstanding
(Diluted) 2,782.0 2,844.8
Effective tax rate 24.7% 24.0%
--------------------
Adjusted earnings before
provision for taxes and
net earnings
Earnings before
provision for taxes
on income $4,263 28.0 $4,415 (1) 26.8 (3.4)
Net earnings $3,208 21.1 $3,367 (1) 20.5 (4.7)
Net earnings per
share (Diluted) $1.15 $1.18 (1) (2.5)
Effective tax
rate 24.7% 23.7%
(1) The difference between as reported and as adjusted earnings before
provision for taxes on income and net earnings and net earnings per
share (diluted) is IPR&D of $40 million with no tax benefit and $0.01
per share, respectively.
Johnson & Johnson and Subsidiaries
-----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except
Per Share Figures) SIX MONTHS
------------------------------ ----------
2009 2008 Percent
---------------- ------------------
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
------------------ ------ -------- ------ -------- ------------
Sales to customers $30,265 100.0 $32,644 100.0 (7.3)
------------------ ------- ----- ------- ----- ----
Cost of products
sold 8,701 28.7 9,365 28.7 (7.1)
Selling,
marketing and
administrative
expenses 9,405 31.1 10,630 32.6 (11.5)
Research &
development
expense 3,156 10.4 3,608 11.1 (12.5)
In-process
research &
development - - 40 0.1
Interest (income)
expense, net 166 0.6 32 0.1
Other (income)
expense, net (69) (0.2) (153) (0.5)
-------------- --- ---- ---- ---- ----
Earnings before
provision for
taxes on income 8,906 29.4 9,122 27.9 (2.4)
Provision for
taxes on income 2,191 7.2 2,197 6.7 (0.3)
---------------- ----- --- ----- --- ----
Net earnings $6,715 22.2 $6,925 21.2 (3.0)
------------ ------ ---- ------ ---- ----
Net earnings per
share (Diluted) $2.41 $2.43 (0.8)
Average shares
outstanding
(Diluted) 2,785.5 2,856.1
Effective tax rate 24.6% 24.1%
------------------
Adjusted earnings before
provision for taxes
and net earnings
Earnings before
provision for
taxes on income $8,906 29.4 $9,162 (1) 28.1 (2.8)
Net earnings $6,715 22.2 $6,965 (1) 21.3 (3.6)
Net earnings per
share (Diluted) $2.41 $2.44 (1) (1.2)
Effective tax
rate 24.6% 24.0%
(1) The difference between as reported and as adjusted earnings before
provision for taxes on income and net earnings and net earnings per
share (diluted) is IPR&D of $40 million with no tax benefit and $0.01
per share, respectively.
REPORTED SALES vs. PRIOR PERIOD ($MM)
-------------------------------------
SECOND QUARTER
--------------------------------------------
% Change
---------------------------------
2009 2008 Reported Operational (1) Currency
---- ---- -------- --------------- --------
CONSUMER SEGMENT (2)
--------------------
SKIN CARE
---------
US 411 379 8.4% 8.4% -
Intl 422 460 -8.3% 3.8% -12.1%
WW 833 839 -0.7% 5.9% -6.6%
BABY CARE
---------
US 104 111 -6.3% -6.3% -
Intl 404 461 -12.4% -1.2% -11.2%
WW 508 572 -11.2% -2.2% -9.0%
ORAL CARE
---------
US 174 185 -5.9% -5.9% -
Intl 212 223 -4.9% 9.5% -14.4%
WW 386 408 -5.4% 2.4% -7.8%
OTC/NUTRITIONALS
----------------
US 679 679 - - -
Intl 631 726 -13.1% 0.6% -13.7%
WW 1,310 1,405 -6.8% 0.3% -7.1%
WOMEN'S HEALTH
--------------
US 152 158 -3.8% -3.8% -
Intl 329 346 -4.9% 8.8% -13.7%
WW 481 504 -4.6% 4.8% -9.4%
WOUND CARE / OTHER
------------------
US 188 182 3.3% 3.3% -
Intl 148 126 17.5% 33.6% -16.1%
WW 336 308 9.1% 15.7% -6.6%
TOTAL CONSUMER
--------------
US 1,708 1,694 0.8% 0.8% -
Intl 2,146 2,342 -8.4% 4.7% -13.1%
WW 3,854 4,036 -4.5% 3.1% -7.6%
* See footnotes below
PHARMACEUTICAL SEGMENT (2)
--------------------------
ACIPHEX/PARIET
--------------
US 128 153 -16.3% -16.3% -
Intl 132 172 -23.3% -10.6% -12.7%
WW 260 325 -20.0% -13.3% -6.7%
CONCERTA
--------
US 233 208 12.0% 12.0% -
Intl 84 71 18.3% 38.0% -19.7%
WW 317 279 13.6% 18.7% -5.1%
DURAGESIC/FENTANYL TRANSDERMAL
------------------------------
US 50 70 -28.6% -28.6% -
Intl 168 202 -16.8% -6.5% -10.3%
WW 218 272 -19.9% -12.3% -7.6%
LEVAQUIN/FLOXIN
---------------
US 343 330 3.9% 3.9% -
Intl 19 21 -9.5% 7.3% -16.8%
WW 362 351 3.1% 4.1% -1.0%
PROCRIT/EPREX
--------------
US 330 346 -4.6% -4.6% -
Intl 247 306 -19.3% -7.6% -11.7%
WW 577 652 -11.5% -6.0% -5.5%
RAZADYNE/REMINYL
----------------
US 16 42 -61.9% -61.9% -
Intl 91 110 -17.3% -4.2% -13.1%
WW 107 152 -29.6% -20.1% -9.5%
REMICADE
--------
US 771 684 12.7% 12.7% -
US Exports (4) 327 200 63.5% 63.5% -
Intl 4 2 100.0% 96.2% 3.8%
WW 1,102 886 24.4% 24.4% -
RISPERDAL/RISPERIDONE
---------------------
US 70 492 -85.8% -85.8% -
Intl 169 220 -23.2% -17.9% -5.3%
WW 239 712 -66.4% -64.8% -1.6%
RISPERDAL CONSTA
----------------
US 131 120 9.2% 9.2% -
Intl 217 223 -2.7% 13.7% -16.4%
WW 348 343 1.5% 12.1% -10.6%
TOPAMAX
-------
US 75 548 -86.3% -86.3% -
Intl 107 129 -17.1% -2.9% -14.2%
WW 182 677 -73.1% -70.4% -2.7%
VELCADE
-------
US - 1 -100.0% -100.0% -
Intl 229 204 12.3% 26.9% -14.6%
WW 229 205 11.7% 26.2% -14.5%
OTHER
-----
US 698 599 16.5% 16.5% -
Intl 859 887 -3.2% 11.3% -14.5%
WW 1,557 1,486 4.8% 13.5% -8.7%
TOTAL PHARMACEUTICAL
--------------------
US 3,172 3,793 -16.4% -16.4% -
Intl 2,326 2,547 -8.7% 3.3% -12.0%
WW 5,498 6,340 -13.3% -8.5% -4.8%
MAJOR NEW PHARMACEUTICAL PRODUCTS (5)
-------------------------------------
PREZISTA
US 65 43 51.2% 51.2% -
Intl 75 45 66.7% 90.0% -23.3%
WW 140 88 59.1% 71.0% -11.9%
INVEGA
US 67 62 8.1% 8.1% -
Intl 32 14 128.6% 163.7% -35.1%
WW 99 76 30.3% 36.6% -6.3%
* See footnotes below
MEDICAL DEVICES AND DIAGNOSTICS (2)(3)
--------------------------------------
CORDIS (6)
----------
US 252 328 -23.2% -23.2% -
Intl 422 485 -13.0% -5.5% -7.5%
WW 674 813 -17.1% -12.6% -4.5%
DEPUY
-----
US 762 722 5.5% 5.5% -
Intl 561 606 -7.4% 6.5% -13.9%
WW 1,323 1,328 -0.4% 6.0% -6.4%
DIABETES CARE
-------------
US 306 338 -9.5% -9.5% -
Intl 304 336 -9.5% 2.2% -11.7%
WW 610 674 -9.5% -3.7% -5.8%
ETHICON
-------
US 452 374 20.9% 20.9% -
Intl 589 646 -8.8% 3.2% -12.0%
WW 1,041 1,020 2.1% 9.7% -7.6%
ETHICON ENDO-SURGERY
--------------------
US 489 484 1.0% 1.0% -
Intl 626 640 -2.2% 10.7% -12.9%
WW 1,115 1,124 -0.8% 6.3% -7.1%
ORTHO-CLINICAL DIAGNOSTICS
--------------------------
US 284 250 13.6% 13.6% -
Intl 210 226 -7.1% 4.2% -11.3%
WW 494 476 3.8% 9.2% -5.4%
VISION CARE
-----------
US 231 227 1.8% 1.8% -
Intl 399 412 -3.2% 2.0% -5.2%
WW 630 639 -1.4% 1.9% -3.3%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
-------------------------------------
US 2,776 2,723 1.9% 1.9% -
Intl 3,111 3,351 -7.2% 3.7% -10.9%
WW 5,887 6,074 -3.1% 2.9% -6.0%
1) Operational growth excludes the effect of currency
2) Select areas (unaudited)
3) Prior year amounts have been reclassified to conform with current
presentation
4) For external purposes, reported as U.S. sales
5) Included in Other
6) Includes sales of Drug-Eluting Stents for Q2 2009 of $69, $165 and
$234 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Q2 2008 of $167, $227 and
$394 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for June YTD 2009 of $136,
$349 and $485 million Domestic, International and Worldwide
respectively
Includes sales of Drug-Eluting Stents for June YTD 2008 of $336,
$458 and $794 million Domestic, International and Worldwide
respectively
SIX MONTHS
--------------------------------------------
% Change
---------------------------------
2009 2008 Reported Operational (1) Currency
---- ---- -------- --------------- --------
CONSUMER SEGMENT (2)
--------------------
SKIN CARE
---------
US 834 761 9.6% 9.6% -
Intl 841 918 -8.4% 4.6% -13.0%
WW 1,675 1,679 -0.2% 6.9% -7.1%
BABY CARE
---------
US 206 226 -8.8% -8.8% -
Intl 791 879 -10.0% 1.5% -11.5%
WW 997 1,105 -9.8% -0.7% -9.1%
ORAL CARE
---------
US 362 384 -5.7% -5.7% -
Intl 389 410 -5.1% 10.4% -15.5%
WW 751 794 -5.4% 2.6% -8.0%
OTC/NUTRITIONALS
----------------
US 1,405 1,521 -7.6% -7.6% -
Intl 1,253 1,478 -15.2% -0.9% -14.3%
WW 2,658 2,999 -11.4% -4.3% -7.1%
WOMEN'S HEALTH
--------------
US 301 306 -1.6% -1.6% -
Intl 603 659 -8.5% 4.9% -13.4%
WW 904 965 -6.3% 2.8% -9.1%
WOUND CARE / OTHER
------------------
US 326 315 3.5% 3.5% -
Intl 254 243 4.5% 19.4% -14.9%
WW 580 558 3.9% 10.4% -6.5%
TOTAL CONSUMER
--------------
US 3,434 3,513 -2.2% -2.2% -
Intl 4,131 4,587 -9.9% 3.6% -13.5%
WW 7,565 8,100 -6.6% 1.0% -7.6%
* See footnotes below
PHARMACEUTICAL SEGMENT (2)
--------------------------
ACIPHEX/PARIET
--------------
US 266 269 -1.1% -1.1% -
Intl 257 333 -22.8% -9.5% -13.3%
WW 523 602 -13.1% -5.7% -7.4%
CONCERTA
--------
US 502 432 16.2% 16.2% -
Intl 159 137 16.1% 37.6% -21.5%
WW 661 569 16.2% 21.4% -5.2%
DURAGESIC/FENTANYL TRANSDERMAL
------------------------------
US 125 145 -13.8% -13.8% -
Intl 324 360 -10.0% 1.8% -11.8%
WW 449 505 -11.1% -2.7% -8.4%
LEVAQUIN/FLOXIN
---------------
US 751 804 -6.6% -6.6% -
Intl 36 43 -16.3% 2.0% -18.3%
WW 787 847 -7.1% -6.2% -0.9%
PROCRIT/EXPREX
--------------
US 651 680 -4.3% -4.3% -
Intl 476 601 -20.8% -8.7% -12.1%
WW 1,127 1,281 -12.0% -6.3% -5.7%
RAZADYNE/REMINYL
----------------
US 29 92 -68.5% -68.5% -
Intl 179 209 -14.4% 0.2% -14.6%
WW 208 301 -30.9% -20.8% -10.1%
REMICADE
--------
US 1,508 1,360 10.9% 10.9% -
US Exports (4) 613 520 17.9% 17.9% -
Intl 9 4 125.0% 118.1% 6.9%
WW 2,130 1,884 13.1% 13.1% -
RISPERDAL/RISPERIDONE
---------------------
US 188 1,074 -82.5% -82.5% -
Intl 326 447 -27.1% -21.3% -5.8%
WW 514 1,521 -66.2% -64.5% -1.7%
RISPERDAL CONSTA
----------------
US 257 221 16.3% 16.3% -
Intl 416 431 -3.5% 13.8% -17.3%
WW 673 652 3.2% 14.6% -11.4%
TOPAMAX
-------
US 570 1,068 -46.6% -46.6% -
Intl 214 255 -16.1% -1.4% -14.7%
WW 784 1,323 -40.7% -37.9% -2.8%
VELCADE
-------
US - 3 -100.0% -100.0% -
Intl 421 386 9.1% 24.5% -15.4%
WW 421 389 8.2% 23.5% -15.3%
OTHER
-----
US 1,386 1,195 16.0% 16.0% -
Intl 1,615 1,700 -5.0% 10.4% -15.4%
WW 3,001 2,895 3.7% 12.7% -9.0%
TOTAL PHARMACEUTICAL
--------------------
US 6,846 7,863 -12.9% -12.9% -
Intl 4,432 4,906 -9.7% 3.1% -12.8%
WW 11,278 12,769 -11.7% -6.8% -4.9%
MAJOR NEW PHARMACEUTICAL PRODUCTS (5)
-------------------------------------
PREZISTA
--------
US 137 75 82.7% 82.7% -
Intl 125 87 43.7% 66.5% -22.8%
WW 262 162 61.7% 73.9% -12.2%
INVEGA
------
US 133 119 11.8% 11.8% -
Intl 57 23 147.8% 186.4% -38.6%
WW 190 142 33.8% 39.9% -6.1%
* See footnotes below
MEDICAL DEVICES AND DIAGNOSTICS (2)(3)
--------------------------------------
CORDIS (6)
----------
US 498 670 -25.7% -25.7% -
Intl 844 944 -10.6% -3.6% -7.0%
WW 1,342 1,614 -16.9% -12.8% -4.1%
DEPUY
-----
US 1,528 1,431 6.8% 6.8% -
Intl 1,087 1,184 -8.2% 6.5% -14.7%
WW 2,615 2,615 - 6.6% -6.6%
DIABETES CARE
-------------
US 576 641 -10.1% -10.1% -
Intl 575 648 -11.3% 0.5% -11.8%
WW 1,151 1,289 -10.7% -4.8% -5.9%
ETHICON
-------
US 857 715 19.9% 19.9% -
Intl 1,137 1,250 -9.0% 3.5% -12.5%
WW 1,994 1,965 1.5% 9.4% -7.9%
ETHICON ENDO-SURGERY
--------------------
US 943 913 3.3% 3.3% -
Intl 1,187 1,214 -2.2% 11.1% -13.3%
WW 2,130 2,127 0.1% 7.3% -7.2%
ORTHO-CLINICAL DIAGNOSTICS
--------------------------
US 561 488 15.0% 15.0% -
Intl 400 431 -7.2% 3.8% -11.0%
WW 961 919 4.6% 9.7% -5.1%
VISION CARE
-----------
US 465 453 2.6% 2.6% -
Intl 764 793 -3.7% 0.5% -4.2%
WW 1,229 1,246 -1.4% 1.3% -2.7%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
-------------------------------------
US 5,428 5,311 2.2% 2.2% -
Intl 5,994 6,464 -7.3% 3.6% -10.9%
WW 11,422 11,775 -3.0% 3.0% -6.0%
1) Operational growth excludes the effect of currency
2) Select areas (unaudited)
3) Prior year amounts have been reclassified to conform with current
presentation
4) For external purposes, reported as U.S. sales
5) Included in Other
6) Includes sales of Drug-Eluting Stents for Q2 2009 of $69, $165 and
$234 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Q2 2008 of $167, $227 and
$394 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for June YTD 2009 of $136,
$349 and $485 million Domestic, International and Worldwide
respectively
Includes sales of Drug-Eluting Stents for June YTD 2008 of $336,
$458 and $794 million Domestic, International and Worldwide
respectively
SOURCE Johnson & Johnson
http://www.jnj.com
Copyright © 2009 PR Newswire. All rights reserved